Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab in relapsed or refractory multiple myeloma
CTR20212970Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of talquetamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Mar 2022; status: active.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20212970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212970.